Remdesivir belongs to the class of antiviral drugs used for the treatment of patients with RNA viruses such as Ebola, hepatitis, and coronaviruses, including MERS and SARS. It is also the first drug used for the treatment of COVID-19 (coronavirus disease 2019) that has been approved for sale in the EU. The drug will be produced at the Irkutsk factory of the Pharmasyntez Group of companies under the trade name Remdeform (INN: Remdesivir).

If a current patent restriction is removed, Pharmasyntez is ready to start manufacturing Remdeform on a priority basis and to provide its supply, first of all, to health facilities in Russia and, when the domestic demand is met, to other countries in need of it.